NanoViricides up on COVID-19 plan

NanoViricides (NYSEMKT:NNVC) has signed a Confidential Disclosure Agreement (“CDA”) with a pharmaceutical company in the Asian region to explore collaborating on the Company’s COVID-19 program.

The Company has already identified certain drug candidates that are active against multiple coronaviruses in cell culture studies.

NanoViricides intends to perform animal studies for the clinical SARS-CoV-2 nanoviricide drug candidate for developing information for entering into first-in-human studies under the FDA or other regulatory agencies.

https://seekingalpha.com/news/3568165-nanoviricides-up-9-premarket-on-covidminus-19-plan